GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » EV-to-FCF

Maxigen Biotech (TPE:1783) EV-to-FCF : 12.10 (As of Apr. 06, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Maxigen Biotech's Enterprise Value is NT$3,224.7 Mil. Maxigen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$266.5 Mil. Therefore, Maxigen Biotech's EV-to-FCF for today is 12.10.

The historical rank and industry rank for Maxigen Biotech's EV-to-FCF or its related term are showing as below:

TPE:1783' s EV-to-FCF Range Over the Past 10 Years
Min: -98.23   Med: 16.82   Max: 60.77
Current: 12.86

During the past 13 years, the highest EV-to-FCF of Maxigen Biotech was 60.77. The lowest was -98.23. And the median was 16.82.

TPE:1783's EV-to-FCF is ranked better than
73.64% of 387 companies
in the Medical Devices & Instruments industry
Industry Median: 25.04 vs TPE:1783: 12.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-06), Maxigen Biotech's stock price is NT$43.35. Maxigen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$2.120. Therefore, Maxigen Biotech's PE Ratio (TTM) for today is 20.45.


Maxigen Biotech EV-to-FCF Historical Data

The historical data trend for Maxigen Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech EV-to-FCF Chart

Maxigen Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.83 33.93 12.74 26.03 13.98

Maxigen Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.03 20.07 24.15 13.26 13.98

Competitive Comparison of Maxigen Biotech's EV-to-FCF

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's EV-to-FCF falls into.


;
;

Maxigen Biotech EV-to-FCF Calculation

Maxigen Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3224.667/266.452
=12.10

Maxigen Biotech's current Enterprise Value is NT$3,224.7 Mil.
Maxigen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$266.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxigen Biotech  (TPE:1783) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Maxigen Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=43.35/2.120
=20.45

Maxigen Biotech's share price for today is NT$43.35.
Maxigen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Maxigen Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxigen Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is mainly engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products. It generates the majority of the revenue from the Biomedical products segment.

Maxigen Biotech Headlines

No Headlines